U.K.’s Verona Explores Cystic Fibrosis Role For Novel Bronchodilator

A U.K. patient charity will fund preclinical studies of RPL554 for cystic fibrosis, Verona’s lead compound already in development for another niche respiratory condition, COPD exacerbations.